A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY WITH AN OPEN LABEL EXTENSION TO EVALUATE THE SAFETY AND EFFICACY OF BRODALUMAB IN SUBJECTS WITH AXIAL SPONDYLOARTHRITIS
- Registry ID
- 20101228
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Study type
- INTERVENTIONAL
- Sponsor
- AMGEN CANADA INC
- Start date
- 2015-05-01
- Last update
- 2015-03-06
Conditions
Related clinical trials
- A MULTICENTER, LONG-TERM EXTENSION STUDY OF 104 WEEKS, INCLUDING A DOUBLE-BLIND, PLACEBO-CONTROLLED 40-WEEK RANDOMIZED WITHDRAWAL-RETREATMENT PERIOD, TO EVALUATE THE MAINTENANCE OF TREATMENT EFFECT OF IXEKIZUMAB (LY2439821) IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS
- A 52-WEEK MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF IXEKIZUMAB (LY2439821) IN BDMARD NAIVE PATIENTS WITH NONRADIOGRAPHIC AXIAL SPONDYLOARTHRITIS
- A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED 16-WEEK STUDY FOLLOWED BY LONG-TERM EVALUATION OF EFFICACY AND SAFETY OF IXEKIZUMAB (LY2439821) IN TNFI-EXPERIENCED PATIENTS WITH RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS
- A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, ACTIVE AND PLACEBO-CONTROLLED 16-WEEK STUDY FOLLOWED BY LONG-TERM EVALUATION OF EFFICACY AND SAFETY OF IXEKIZUMAB (LY2439821) IN BDMARD-NAIVE PATIENTS WITH RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS,
View on source registry